Timothy Lu

338 posts

Timothy Lu

@timlu

Synthetic Biologist | Biotech Entrepreneur | MIT Professor

Bergabung Nisan 2007

793 Mengikuti4.7K Pengikut

Timothy Lu me-retweet

Senti Biosciences@SentiBio·11 Ara

Dr. Kanya Rajangam, Chief Medical Officer, emphasized that the encouraging SENTI-202 data support advancement into pivotal studies and exploration across additional patient populations, enabled by recent RMAT and Orphan Drug Designations. bit.ly/3XFf7ST $SNTI #ASH2025

English

1.2K

Timothy Lu@timlu·11 Ara

Thanks to Dr. Farhad Ravandi from @MDAndersonNews for sharing thoughts on the potential for $SNTI's SENTI-202 product to transform the treatment of AML and other cancers. Published by @VJHemOnc vjhemonc.com/video/nvzwt-du…

English

818

Timothy Lu@timlu·11 Ara

Thanks to @GeneOnlineNews for highlighting @SentiBio 's recent SENTI-202 data for R/R AML @ ASH. With 50% ORR, RMAT designation, favorable safety, off-the-shelf delivery, we hope to advance this program quickly into pivotal studies for patients in need geneonline.com/senti-bio-wins…

English

567

Timothy Lu@timlu·10 Ara

$SNTI recently reported our Logic Gated SENTI-202 cell therapy achieved 50% ORR, 42% CR/CRh, 7.6 month cCR durability in heavily pretreated refractory/refractory AML patients at #ASH25. This is an exciting new treatment modality for R/R AML, a disease with a median OS ~5 months

Senti Biosciences@SentiBio

Dr. Nosha Farhadfar noted that SENTI-202 is demonstrating deep, durable responses and a favorable safety profile in R/R AML, underscoring its potential to selectively target AML cells while preserving healthy ones. bit.ly/3XFf7ST $SNTI #AML #ASH2025

English

Timothy Lu@timlu·10 Ara

@drpatrick @BillOReilly @drpatrick I agree with the power of NK cells. @SentiBio just presented exciting data at #ASH2025 showing that SENTI-202 Logic Gated CAR-NK cells are able to generate deep, durable responses in relapsed/refractory AML with a well tolerated safety profile

English

135

Dr. Pat Soon-Shiong@DrPatrick·19 Kas

Thank you @BillOReilly for making your audience aware of the power of natural killer (NK) cells. The first responder against cancer. The show will air on Tuesday and on Thanksgiving day.

Bill O'Reilly@BillOReilly

What if everything we thought we knew about cancer was wrong? @ChrisCuomo sits down with @drpatrick on a breakthrough that will astound you — “Killing Cancer” Tuesday, November 25, at 10p/9C only on NewsNation. To find NewsNation on your screen: NewsNationNow.com

English

248

1.3K

61.3K

Timothy Lu me-retweet

Senti Biosciences@SentiBio·12 Eyl

If you missed our CEO, Tim Lu, at the H.C. Wainwright 27th Annual Global Investment Conference, don’t worry — you can watch the full presentation now! 🎥 Replay available here: bit.ly/4mK46dE $SNTI #CellTherapy #AML #CARNK #AcuteMyeloidLeukemia

English

969

Timothy Lu@timlu·28 Nis

@AACR @SarahCannonDocs Thank you to Dr. Strickland for presenting @SentiBio's SENTI-202 program at #AACR25 yesterday. We're excited to continue advancing our Logic Gated cell therapies for difficult cancers! $SNTI

English

126

AACR@AACR·27 Nis

SENTI-202, an off-the-shelf, logic-gated, CAR natural killer cell therapy drove complete remission of pretreated blood cancers in a first-in-human trial, according to results presented by Stephen Strickland Jr., MD, MSCI: aacr.org/about-the-aacr… #AACR25 @SarahCannonDocs

English

2.8K

Timothy Lu@timlu·28 Nis

Excited to share updates on Senti Bio’s SENTI-202 program with Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML. Come join us at 830 AM ET webinar! $SNTI investors.sentibio.com/news-releases/…

English

1.4K

Timothy Lu@timlu·28 Nis

@jortiz81 Awesome!

English

Jorge Ortiz@jortiz81·26 Nis

Tenured 🥂

English

4.7K

Timothy Lu me-retweet

Senti Biosciences@SentiBio·3 Nis

Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025 bit.ly/3QYtOx5 @AACR

English

291

609

5.7K

9.7M

Timothy Lu me-retweet

Senti Biosciences@SentiBio·25 Nis

#MarkYourCalendars: $SNTI leadership will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at #AACR2025 on Monday, April 28, 2025, at 8:30 AM ET. Access it here: bit.ly/3S668ap #CellTherapy #CARNK #AML @AACR

English

2.1K

Timothy Lu me-retweet

Senti Biosciences@SentiBio·3 Nis

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 bit.ly/3QYtOx5 $SNTI #CellTherapy #CARNK @AACR #AACR25

English

295

565

11.4M

Timothy Lu@timlu·3 Nis

Excited to share the latest clinical and preclinical data on our Logic Gated SENTI-202 product at the upcoming AACR meeting!

Senti Biosciences@SentiBio

English

750

Timothy Lu@timlu·3 Ara

Very excited to share details on SENTI-202 clinical trial - 2 of 3 pts achieved MRD negative CR in 1st dose level evaluated with a generally well-tolerated preliminary safety profile. Both patients continue to maintain remission (4+ and 3+ months, respectively). $SNTI

Senti Biosciences@SentiBio

Today, we announced positive initial clinical data from the Phase 1 trial of SENTI-202, a potential first-in-class, off-the-shelf #CARNK #celltherapy for R/R hematologic malignancies, including #AML. Learn more on our webcast on Dec. 3 at 7:30am ET: bit.ly/4eUaKtb $SNTI

English

2.3K

Timothy Lu@timlu·3 Ara

Excited to share the detailed data on SENTI-202 with Dr. Stephen Strickland and Dr. Kanya Rajangam. Join us to learn about how our #genecircuits enhanced CAR-NK therapies have the potential to transform the treatment of cancer through Logic Gating. $SNTI

Senti Biosciences@SentiBio

Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: bit.ly/4eUaKtb $SNTI

English

2.2K

Timothy Lu me-retweet

Senti Biosciences@SentiBio·3 Ara

English

3.8K

Timothy Lu@timlu·28 Haz

Congratulations to @SentiBio for its $8M award from California Institute for Regenerative Medicine (CIRM) for its Logic-Gated SENTI-202 clinical trial for relapsed/refractory AML. Thanks so much to CIRM for this support! $SNTI cirm.ca.gov/about-cirm/new…

English

1.3K

Timothy Lu me-retweet

Amir Shanehsazzadeh@amirshanehsaz·12 Ara

We @abscibio are excited to unveil IgDesign™ @NeurIPSConf and present our work at @workshopmlsb @AI4D3 @genbio_workshop! IgDesign is an antibody inverse folding model that we have experimentally validated in our lab. Read the paper here: biorxiv.org/content/10.110… #NeurIPS2023

English

133

21K

Timothy Lu@timlu·29 Ağu

Check out how $SNTI's Logic Gates precisely discriminate between cancer cells and healthy cells, allowing us to achieve highly precise cancer therapeutics! #synbio

Senti Biosciences@SentiBio

At Senti, we envision a world where #cancer patients can access smarter therapies that precisely kill their cancer cells and spare their healthy cells. Watch to learn how we're utilizing our proprietary Logic Gating technology to design #CARNK cell therapies to achieve this goal.

English

3.7K

Timothy Lu@timlu·10 Ağu

Exciting times for @SentiBio as we gain extra fuel to power our Gene Circuit enhanced cell therapies to patients.

Senti Biosciences@SentiBio

Today, we announced that Celadon Partners will acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies. Learn more: bit.ly/3KzwjmH

English

5.9K

Jelajahi

@MDAndersonNews @VJHemOnc @GeneOnlineNews @SentiBio @drpatrick @BillOReilly @AACR @SarahCannonDocs